# Evolved Hypotheses — Cycle 2

**Session:** 2026-03-26-targeted-001
**Evolver model:** claude-sonnet-4-6
**Cycle:** 2 (evolved from Cycle 1 top-3)
**Generated:** 2026-03-26
**Operations applied:** Specification (H4-v2), Mandatory Revision + Sequential Reframing (H2-v2), Mutation + Crossover (H5-v2)

---

## Evolution Quality Check (Pre-Output)

**Diversity check — primary mechanosensors in Cycle 2 set:**

| ID | Primary mechanosensor | Bridge mechanism |
|----|----------------------|-----------------|
| H4-v2 | Lamin A/C → LAD geometry (nuclear architecture filter) | Nuclear lamina stiffness scaling creates spatial whitelist for H3K27ac gain |
| H2-v2 | KDM6B (sequential) → EP300 (gated by demethylation) | Sequential enzymatic gate: demethylation unlocks acetylation at bivalent enhancers |
| H5-v2 | MRTF/SRF (actin-polymerization mechanosensor, YAP-independent) | CArG-enhancer remodeling by a mechanosensitive TF orthogonal to TEAD |

All three bridge mechanisms are distinct: nuclear architecture filtering, sequential enzymatic gating, and TF-orthogonal CArG-element remodeling. The diversity constraint is satisfied.

**Critic systematic gap coverage:**
- MRTF/SRF enhancer program: addressed in H5-v2 (full mutation to this mechanosensor)
- Temporal dynamics: addressed in H2-v2 (two-phase sequential model replaces simultaneous coordination claim)
- All mandatory revisions from Critic incorporated (see individual hypotheses below)

---

## H4-v2: Constitutive LAD Enhancers as Hard-Wired Stiffness Resistance Nodes — Lamin A/C Tethering Creates a Binary Mechanical Gate Encoded in Nuclear Geometry

**Parent:** H4 — operation applied: specification + mandatory revision
**Evolution rationale:** Three changes from parent: (1) Replaces the weak ">90% non-LAD" prediction with a properly null-controlled enrichment test that separates constitutive LADs (cLADs, invariant across cell types) from facultative LADs (fLADs, cell-type-variable), which sharpens the testable prediction and narrows the claim to the subset most mechanistically grounded. (2) Replaces the siLMNA perturbation (confounded by nuclear shape changes affecting YAP dynamics) with lamin A point mutant R386K (or LMNA-delta50/progerin-like truncation that retains nuclear stiffness but weakens chromatin tethering) to isolate LAD-anchoring from nuclear shape. (3) Adds an explicit odds-ratio prediction (OR > 4 for stiffness-resistance of TEAD-motif enhancers inside cLADs vs outside) that has statistical power with current CUT&Tag sample sizes.

**Novelty claim:** Sun 2020 demonstrated that nuclear-interior genes gain H3K9me3 demethylation under force while nuclear-periphery genes resist. No study has (a) tested this principle specifically at H3K27ac-accessible enhancers rather than gene bodies, (b) separated constitutive from facultative LAD enhancers as a mechanistically distinct subclass, or (c) asked whether the lamin A/C stiffness-scaling (Swift et al., Science 2013) amplifies this resistance specifically for cLAD enhancers. The hypothesis predicts that cLAD-embedded TEAD-motif enhancers are stiffness-resistant with an odds ratio >4 over non-LAD TEAD enhancers — a quantitative threshold that exceeds the ~1.4x expected from random LAD composition (65% non-LAD genome-wide) and is achievable with 3 biological replicates of H3K27ac CUT&Tag at 10 million reads per sample.

**Mechanism:**

Step 1 — Stiff ECM (>5 kPa) upregulates lamin A/C expression (lamin A:B ratio scales linearly with tissue stiffness across 0.1-40 kPa; Swift et al., Science 2013 [GROUNDED: Dennis Discher lab; confirmed in multiple cell types]) and stabilizes the nuclear lamina via LINC complex-mediated cytoskeletal coupling (emerin-SUN2-nesprin axis). This increases the mean residence time of constitutive LAD chromatin at the nuclear periphery. Constitutive LADs are defined by DamID-seq as domains present at the nuclear periphery in >80% of cells regardless of cell type or differentiation state (Guelen et al., Nature 2008; Kind et al., Cell 2015 [GROUNDED]).

Step 2 — Within constitutive LADs, chromatin is maintained in H3K9me2/3-enriched, H3K27ac-depleted state by a lamin-dependent mechanism: LAD anchoring positions these domains in proximity to nuclear lamina-resident HDAC complexes (HDAC2/3 at the lamina; LMNA-HDAC2 STRING: 0.690 [GROUNDED from computational validation]) and heterochromatin-spreading factors (HP1 proteins). H3K27me3/H3K9me3 at cLADs is maintained by physical proximity to these silencing complexes, not merely by chromatin sequence composition. This creates a position-dependent silencing mechanism that is resistant to cytoplasmic signals.

Step 3 — The mechanical selectivity filter: when stiff ECM activates YAP nuclear translocation and EP300-dependent H3K27ac deposition, EP300 can act on euchromatic non-LAD enhancers (accessible nucleosomes, low H3K9me3) but is sterically and biochemically excluded from cLAD-embedded enhancers (compact chromatin, high H3K9me3 that competes with H3K27 acetylation, HDAC2 proximity). The filter is therefore set by nuclear geometry — which enhancers are physically in cLADs — not by TF binding motif composition. Critical prediction: TEAD-motif-containing enhancers in cLADs should NOT gain H3K27ac on stiff ECM, while identical TEAD-motif enhancers in non-LAD euchromatin gain H3K27ac readily. This creates a stiffness-insensitive set of TEAD sites that is invisible to transcription-factor-centric models of YAP target gene regulation.

Step 4 — The lamin A/C reinforcement amplification: increased lamin A/C on stiff ECM (Step 1) tightens cLAD anchoring and potentially recruits additional HDAC2 to LAD-associated chromatin, further widening the activation gap between non-LAD and cLAD enhancers. This produces a quantitative prediction: the odds ratio for stiffness-responsiveness (H3K27ac gain >2-fold) of non-LAD TEAD enhancers vs cLAD TEAD enhancers should be higher on stiff ECM (10-25 kPa) than on soft ECM (1-3 kPa), where the lamin A/C level is lower and the filter is weaker. The filter should be dose-dependent with ECM stiffness.

Step 5 — Separating cLAD from fLAD: facultative LADs (present at the periphery in only some cell types) contain developmentally regulated genes whose enhancers may relocate to the nuclear interior during commitment. For fLAD enhancers, the filter effect should be cell-type-specific and context-dependent. The strong prediction applies only to cLAD enhancers. This means the experiment must stratify enhancers by cLAD vs fLAD identity using cell-type-matched DamID-seq or publicly available ENCODE lamin B1 ChIP-seq (which identifies LAD positions in the same cell line used for stiffness experiments).

**Predicted observation:** MCF10A cells on PAA hydrogels at 1 kPa and 10 kPa (n=3 biological replicates per stiffness, 48 hr culture). H3K27ac CUT&Tag + lamin B1 CUT&RUN (defining LADs in the same cells). Computational analysis:

(a) TEAD1-motif-containing enhancers (from TEAD1 motif scan, n ~ 8,000-12,000 genome-wide) are stratified into cLAD (overlap with ENCODE cLAD, ≥80% cell-type prevalence), fLAD (overlap with cell-type-specific LAD), and non-LAD subsets.

(b) Primary prediction: the odds ratio for H3K27ac gain (>2-fold between 1 kPa and 10 kPa) in non-LAD TEAD enhancers vs cLAD TEAD enhancers will exceed 4.0 (i.e., non-LAD TEAD enhancers are at least 4x more likely to be stiffness-responsive than cLAD TEAD enhancers). This is a strong effect estimate based on the expected complete suppression of stiffness-responsiveness in the cLAD fraction.

(c) Secondary prediction: the effect is graded with stiffness — odds ratio at 10 kPa > odds ratio at 5 kPa > odds ratio at 3 kPa, reflecting lamin A/C scaling.

(d) Perturbation using LMNA-R386K point mutant (maintains nuclear stiffness and shape; selectively weakens chromatin tethering to the lamina due to mutation in the tail domain interaction interface) transiently expressed in MCF10A: cLAD TEAD enhancers should partially gain H3K27ac on stiff ECM when lamin tethering is disrupted, while nuclear YAP dynamics are preserved. If this rescue occurs, it confirms that LAD anchoring (not nuclear shape or YAP signaling) is the mechanistic gate.

**Falsification:**

(1) If cLAD TEAD enhancers and non-LAD TEAD enhancers gain H3K27ac at similar rates on stiff ECM (OR < 2), the LAD filter is not operating and chromatin accessibility or TF binding affinity differences explain stiffness-responsiveness.

(2) If LMNA-R386K does NOT partially rescue H3K27ac at cLAD TEAD enhancers on stiff ECM (while non-LAD enhancers remain responsive), lamin A/C-mediated LAD tethering is not the barrier — another mechanism (H3K9me3 maintained by SUV39H1/2 independently of lamin) is responsible for the resistance.

(3) If fLAD and cLAD enhancers show equivalent stiffness resistance, the cLAD/fLAD distinction is not biologically meaningful for this question and the "invariant mechanical filter" concept is incorrect.

**Test protocol:** MCF10A cells (ATCC CRL-10317) on polyacrylamide hydrogels (1, 5, 10, 25 kPa; n=3 biological replicates per stiffness). 48 hr culture in complete MCF10A medium (serum + EGF). Primary assay: H3K27ac CUT&Tag (Epicypher SNAP-CUTANA kit, anti-H3K27ac antibody) + lamin B1 CUT&RUN (anti-lamin B1, ab16048) to define cell-type-specific LAD boundaries in the same cells. RNA-seq for transcriptome changes. Compute: odds ratio for H3K27ac gain at cLAD vs non-LAD TEAD-motif enhancers at each stiffness; logistic regression with enhancer GC content, CpG density, and nearest gene expression as covariates. Perturbation: transient transfection of LMNA-R386K plasmid (or doxycycline-inducible LMNA-delta50 if stable line) 24 hr before transfer to stiff ECM. Western blot for lamin A/C, lamin B1, YAP (nuclear vs cytoplasmic fractionation), and HDAC2 at each stiffness. H3K9me3 CUT&Tag as secondary mark to confirm that cLAD enhancers maintain repressive chromatin on stiff ECM.

**Confidence:** 0.60 — Increased from parent (0.50) because: (a) the cLAD vs fLAD stratification generates a sharper, better-powered prediction; (b) the LMNA-R386K perturbation cleanly dissects lamin tethering from nuclear shape/YAP dynamics; (c) the lamin A/C — HDAC2 connection (STRING 0.690) provides a biochemical route for why LAD-embedded enhancers specifically experience more HDAC opposition than non-LAD enhancers on stiff ECM.

**Groundedness:** 8 — All parent claims remain: LAD biology (Guelen 2008, Kind 2015), lamin A/C stiffness-scaling (Swift 2013), Sun 2020 interior/periphery differential, LMNA-HDAC2 interaction (STRING 0.690 from computational validation). The new cLAD/fLAD distinction is grounded in published DamID-seq data from the van Steensel lab (Peric-Hupkes et al., Mol Cell 2010 [GROUNDED]). The LMNA-R386K point mutant is a published reagent (used in progeria research; weakens tail domain interactions with chromatin). The only parametric claim is the OR > 4 threshold — this is a model prediction, not a measured value.

**Key uncertainty:** Whether LMNA-R386K sufficiently weakens LAD tethering in MCF10A without off-target effects on the Hippo pathway (lamin A/C mutations are known to affect nuclear pore distribution which affects YAP transport). The ideal control is nuclear YAP localization in LMNA-R386K cells on stiff ECM; if YAP nuclear entry is unchanged relative to WT lamin A, the perturbation is clean.

**Counter-evidence:**

(1) Some cLAD-embedded TEAD enhancers may be activated in cancer contexts even without LAD relocation (Rao et al. have shown that super-enhancers can form within heterochromatic regions in highly amplified oncogene loci). If this occurs under physiological stiffness, the filter concept is wrong for cancer models.

(2) Lamin A/C upregulation on stiff ECM could reorganize LAD boundaries (causing some fLADs to become cLADs, or some cLADs to relocate) rather than uniformly reinforcing existing LADs. If LAD geometry is dynamic on the timescale of stiffness sensing (48 hr), the "filter" is not a stable structural feature but a moving boundary.

(3) HDAC2 at the nuclear lamina was established primarily in quiescent cells; in proliferating cells (MCF10A under normal culture), the lamina-HDAC2 complex may be disrupted during DNA replication, introducing cell-cycle-dependent variability.

**Cross-domain creativity score:** 3 (mechanobiology + nuclear architecture/3D genome organization + computational genomics)

---

## H2-v2: Sequentially Gated Bivalent Enhancer Activation — KDM6B Demethylation as Rate-Limiting Mechanical Gate Precedes EP300 Acetylation at Developmental Loci in MSCs

**Parent:** H2 — operation applied: mandatory revision + sequential reframing (reframes simultaneous coordination as ordered two-phase mechanism)
**Evolution rationale:** The Critic identified the temporal asynchrony as a near-fatal flaw: EP300/YAP acts at 15-60 min while KDM6B is transcriptionally induced over 4-8 hr. Rather than defending simultaneous coordination, this evolution reframes the relationship as a SEQUENTIAL GATE — demethylation is the rate-limiting step that enables acetylation, not a co-occurring event. This is a stronger and more mechanistically specific model. Four additional changes: (a) adds separate siKDM6B and siKDM6A experiments (not just GSK-J4, which inhibits both) to establish which demethylase operates at enhancers; (b) uses A-485 + SGC-CBP30 combination for complete HAT blockade; (c) explicitly acknowledges the Yu 2025 thyroid cancer / MSC extrapolation; (d) replaces the "stripped enhancer state" prediction (vulnerable to rapid PRC2 re-methylation) with a kinetically resolved prediction: early time point (4 hr) will show incomplete acetylation if demethylation has not occurred, late time point (24 hr) will show full bivalent-to-active conversion.

**Novelty claim:** No paper has tested whether KDM6B (or UTX/KDM6A) acts as a rate-limiting gate for EP300-dependent H3K27ac deposition at bivalent developmental enhancers under ECM stiffness gradients. The sequential model — demethylation must precede acetylation on the same H3K27 residue, and this ordering produces a temporal signature detectable by ChIP time-courses — is unexplored. Yu 2025 showed KDM6B induction by ECM stiffness in thyroid cancer (at promoters). Whitworth 2024 showed EP300 requirement for mechanosensitive gene activation under shear stress. The combinatorial claim (KDM6B demethylation as the temporal bottleneck that determines WHICH developmental enhancers are activated by EP300 under stiffness, and WHEN) is novel. Specifically: the hypothesis predicts that KDM6B knockdown on stiff ECM will produce a distinctive "frozen bivalent" enhancer state that persists for longer than predicted if the two enzymes were acting independently — because without demethylation, EP300 cannot acetylate H3K27 on nucleosomes carrying H3K27me3 (mutual exclusivity is the mechanistic constraint).

**Mechanism:**

Step 1 — Bivalent enhancers at developmental gene loci (RUNX2, SOX9, PPARG in MSCs) carry H3K4me1 (monomethylation by MLL3/4-COMPASS, marking enhancer identity) and H3K27me3 (by PRC2/EZH2, maintaining poised silencing) on the same or adjacent nucleosomes [GROUNDED: Rada-Iglesias et al., Nature 2011; the poised enhancer state is established in human ESCs and maintained in undifferentiated MSCs]. These bivalent enhancers are transcriptionally silent because H3K27me3 prevents RNA Pol II elongation and blocks BRD4 bromodomain binding.

Step 2 — ECM stiffness (10-40 kPa; MSC osteogenic range) induces KDM6B (JMJD3) expression via an NF-kB- or EGR1-dependent transcriptional mechanism [PARAMETRIC for NF-kB route: KDM6B is an NF-kB target in inflammatory contexts; whether the same mechanism operates under stiffness in MSCs is untested]. KDM6B protein accumulates over 4-8 hr on stiff substrates [extrapolated from Yu 2025 (thyroid cancer cells, PAA substrates, 4-24 hr timecourse — cell type caveat acknowledged]. KDM6B demethylates H3K27me3 via a Fe(II)/alpha-ketoglutarate-dependent JmjC domain mechanism (t1/2 for demethylation of a single nucleosome in vitro: ~20-40 min; in vivo, likely slower due to chromatin compaction). The demethylation is substrate-context-dependent: KDM6B has highest activity on H3K27me3 in the context of transcriptionally poised regions (nucleosomes with histone H2A.Z, found at bivalent enhancers) rather than heterochromatic H3K27me3.

Step 3 — SEQUENTIAL GATE MODEL: Demethylation of H3K27me3 at bivalent enhancers by KDM6B (occurring 4-8 hr after stiffness stimulus) creates unmodified H3K27 — now accessible to EP300 acetyltransferase activity. However, EP300 is already recruited to these loci by 15-60 min (via YAP nuclear translocation). The hypothesis proposes that EP300 activity is STALLED at bivalent enhancers with H3K27me3 — not because EP300 lacks activity, but because the nucleosome substrate is in a compact, PRC2-dependent conformation that reduces EP300 accessibility to H3K27. Once KDM6B demethylates H3K27me3 and disrupts PRC2 binding, EP300 catalyzes rapid H3K27ac deposition in a "burst" — the pre-positioned enzyme converts the newly unmodified H3K27 in a burst of acetylation that takes 30-120 min after the demethylation event.

Step 4 — Kinetic signature of the sequential model: the two-phase model predicts a distinctive time-course at bivalent enhancers:
- 0-2 hr: H3K27me3 stable, H3K27ac absent (EP300 present but stalled at compact bivalent chromatin)
- 4-8 hr: H3K27me3 declining (KDM6B accumulating and acting), H3K27ac still absent (demethylation incomplete)
- 8-16 hr: H3K27me3 low, H3K27ac rising sharply (burst acetylation by pre-positioned EP300 on newly demethylated H3K27)
- 16-72 hr: H3K27ac stable, H3K27me3 absent (enhancer fully converted to active state)

This temporal signature (the "lag phase" followed by "burst") distinguishes the sequential gate from a simple EP300-activity model (which would predict monotonically increasing H3K27ac from t=0) and from independent parallel pathways (which would show no lag).

Step 5 — Enhancer-specificity determinants: the gate operates specifically at bivalent enhancers (H3K4me1+/H3K27me3+) and not at: (a) already-active enhancers (H3K4me1+/H3K27ac+, which lack KDM6B substrate), (b) Polycomb-repressed promoters (H3K27me3+/H3K4me3+, where KDM6B may act but EP300 is not a typical partner), or (c) H3K9me3-marked LAD enhancers (H4-v2's domain — different repressive pathway). The sequential gate is therefore specific to the bivalent enhancer class.

**Predicted observation:** Human bone marrow MSCs (Lonza PT-2501) on PAA hydrogels at 1 kPa (soft), 10 kPa (intermediate), and 40 kPa (stiff). Time course: cells transferred to stiff ECM (40 kPa) from tissue culture plastic; CUT&Tag for H3K27me3, H3K27ac, and H3K4me1 at 0, 2, 4, 8, 16, 24, and 72 hr post-transfer (n=2 replicates per timepoint; CUT&Tag on 100,000 cells per sample is feasible).

Primary predictions:
(a) H3K4me1+/H3K27me3+ (bivalent) enhancers near RUNX2, SP7/Osterix, DLX5 are present at t=0 on soft ECM.
(b) H3K27me3 at these enhancers begins declining at 4-8 hr post-transfer to stiff ECM (lag consistent with KDM6B protein accumulation timescale).
(c) H3K27ac at the same loci begins rising at 8-16 hr — after, not before, H3K27me3 decline (the sequential signature).
(d) A 2-hr stiff ECM pulse followed by return to soft ECM does NOT activate these enhancers (insufficient KDM6B induction), but a 8-hr pulse does (KDM6B has been induced and demethylated H3K27me3).

Perturbation:
(e) siKDM6B (JMJD3; targeting exon 15-16 junction to avoid homology with KDM6A): stiff ECM should produce H3K27me3 persistence at bivalent enhancers AND reduced/delayed H3K27ac gain, specifically at H3K4me1+/H3K27me3+ loci. Control siKDM6A (UTX): tests whether UTX is the relevant demethylase at these specific enhancers (expect partial phenotype since UTX is the enhancer-associated paralog).
(f) A-485 (3 uM, EP300) + SGC-CBP30 (10 uM, CBP) combination: full HAT blockade should prevent H3K27ac deposition even after KDM6B has demethylated H3K27me3, producing the transient "unmodified H3K27" state at these loci — detectable as loss of both marks at 8-16 hr but restoration of H3K27me3 by 24 hr (PRC2 re-methylation of unprotected H3K27). This transient stripped state would confirm the sequential model.

**Falsification:**

(1) If H3K27ac at bivalent enhancers begins rising before 4 hr (before KDM6B protein can accumulate), the sequential gate model is wrong and EP300 can acetylate H3K27 regardless of H3K27me3 status.

(2) If siKDM6B does not preserve H3K27me3 at bivalent enhancers on stiff ECM and siKDM6A fully phenocopies the GSK-J4 result, then UTX (not KDM6B) is the relevant demethylase and the stiffness-regulated demethylase is UTX (which would require a different upstream regulatory mechanism than KDM6B induction).

(3) If the 4-hr stiff ECM pulse is sufficient to activate bivalent enhancers, the rate-limiting step is not KDM6B (which requires >4 hr to be transcriptionally induced), and either constitutive UTX activity or a faster post-translational KDM6B activation mechanism operates.

(4) If H3K27ac kinetics at bivalent enhancers are not systematically delayed relative to non-bivalent TEAD enhancers (i.e., if there is no lag phase), the sequential gate is not operating and the two enzymes are independent.

**Test protocol:** Human bone marrow MSCs (Lonza PT-2501; n=3 donor lines to control for inter-donor variability). PAA hydrogels: 1 kPa (soft), 10 kPa (intermediate), 40 kPa (stiff). Transfer protocol: MSCs at passage 3-5 on tissue culture plastic, transferred to PAA hydrogels in growth medium (no differentiation supplements — this isolates mechanical effects from soluble differentiation signals). CUT&Tag for H3K27me3 (anti-H3K27me3, CST #9733), H3K27ac (anti-H3K27ac, Abcam ab4729), H3K4me1 (anti-H3K4me1, Abcam ab8895) at t=0, 2, 4, 8, 16, 24, 72 hr post-transfer. KDM6B western blot and CUT&RUN at same timepoints to confirm KDM6B protein accumulation and genomic occupancy timecourse. siRNA: siKDM6B (JMJD3) + siKDM6A (UTX) as separate conditions, n=3 per condition. HAT inhibition: A-485 (3 uM) + SGC-CBP30 (10 uM, Sigma-Aldrich SML1500) applied at t=0 (transfer to stiff ECM); harvest at 8, 16, and 24 hr. RRBS (reduced representation bisulfite sequencing) on a subset of samples to rule out DNA methylation changes as confounders at the same time window. Bioinformatics: overlap enhancer H3K27me3/H3K27ac dynamics with H3K4me1-defined bivalent enhancer set; calculate lag between H3K27me3 loss and H3K27ac gain at each bivalent enhancer locus using cross-correlation.

**Confidence:** 0.55 — Increased from parent (0.60 adjusted down to 0.50 by Critic) because: the sequential reframing removes the mechanistic flaw identified by the Critic (temporal asynchrony) and converts it into the testable prediction. The KDM6B vs UTX question is now the key uncertainty rather than a confound. The dual-HAT inhibitor (A-485 + SGC-CBP30) removes the CBP compensation loophole. The time-course design directly tests the lag-phase signature.

**Groundedness:** 7 — Bivalent enhancer biology (Rada-Iglesias 2011) [GROUNDED]. KDM6B stiffness-induction (Yu 2025, thyroid cancer) [GROUNDED, with cell-type caveat]. EP300 mechanosensitive activity (Whitworth 2024, shear stress) [GROUNDED, with stiffness vs shear caveat]. H3K27me3/H3K27ac mutual exclusivity [canonical biochemistry, GROUNDED]. SGC-CBP30 as CBP-selective inhibitor [GROUNDED: published tool compound]. The sequential gate model (EP300 stalled by PRC2-dependent chromatin compaction) is PARAMETRIC — no paper has directly shown EP300 stalling at bivalent H3K27me3-marked enhancers. The siKDM6B vs siKDM6A dissection is GROUNDED in principle but the cell-type-specific enhancer preference of each enzyme in MSCs is untested.

**Key uncertainty:** Whether KDM6B (vs UTX) operates at DISTAL ENHANCERS in MSCs. Yu 2025 showed KDM6B at promoters in thyroid cancer cells. UTX is the enhancer-associated paralog (Herz et al., Nat Struct Mol Biol 2012 showed UTX as part of MLL3/4-COMPASS which deposits H3K4me1 at enhancers). If the siKDM6A experiment shows UTX as the relevant demethylase, the hypothesis remains valid but requires reattribution from KDM6B to UTX. The stiffness-responsiveness of UTX expression or activity in MSCs is unknown.

**Counter-evidence:**

(1) PRC2/EZH2 is actively recruited to bivalent enhancers by Ring1B (PRC1) and can rapidly re-methylate H3K27 once demethylated (re-methylation t1/2 ~2-4 hr in many contexts). The competition between KDM6B demethylation and PRC2 re-methylation at stiffness-induced bivalent enhancers may produce oscillatory rather than monotonic H3K27me3 loss, complicating the kinetic signature interpretation.

(2) EP300 substrate preference may not be strongly influenced by adjacent H3K27me3 — EP300 can acetylate H3K27 on nucleosomes pre-modified with H3K27me3 in vitro (though this is competitively inhibited). If EP300 is not stalled by H3K27me3 in vivo, the "lag phase" would not exist and the sequential gate model collapses.

(3) The 4-8 hr timescale for KDM6B protein accumulation requires transcriptional induction. If KDM6B is regulated post-translationally by stiffness (e.g., phosphorylation stabilizing existing KDM6B protein) rather than transcriptionally, it could act earlier, eliminating the lag phase without changing the core mechanism.

**Cross-domain creativity score:** 2 (mechanobiology + developmental epigenomics + chromatin kinetics)

---

## H5-v2: MRTF/SRF-Dependent CArG Enhancer Remodeling Under ECM Stiffness — A YAP-Independent Mechanosensitive Enhancer Program with Distinct Nuclear Localization Preferences

**Parent:** H5 — operation applied: mutation (mechanosensor swap: YAP/BRD4 → MRTF/SRF) + crossover with H4 (nuclear architecture localization insight applied to a new TF)
**Evolution rationale:** The parent H5 (EP300-BRD4 mechanical memory via positive feedback) faces a quantitative fatal flaw: H3K27ac half-life of 2-6 hr makes the claimed 24-72 hr memory period implausible without an effectively infinite feedback gain. The Critic recommended lowering the memory duration to 6-24 hr, but even this requires a feedback loop that sustains EP300 recruitment at specific loci after YAP has exited — which is mechanistically unsupported for BRD4 (a general H3K27ac reader, not a locus-specific recruiter). Rather than patching these compounding weaknesses, this evolution performs a mechanosensor swap: the MRTF/SRF pathway (RhoA → actin polymerization → MRTF-A/B nuclear → SRF binds CArG elements) is a well-characterized YAP-independent mechanosensing pathway (Olson and Nordheim, Nat Rev Mol Cell Biol 2010) that operates in the same stiffness range (5-25 kPa) but activates a completely different set of enhancers (SRF/CArG elements, not TEAD elements). The crossover with H4 asks: do MRTF/SRF-activated CArG enhancers also show LAD-based spatial partitioning? The critical insight is that MRTF and YAP have partially overlapping cytoplasmic retention mechanisms (both regulated by F-actin status) but different nuclear targets — which means MRTF defines a second mechanical enhancer program orthogonal to YAP/TEAD. No paper has profiled the MRTF/SRF-dependent enhancer landscape under ECM stiffness gradients, nor compared it to the YAP/TEAD enhancer program at the same stiffness conditions.

**Novelty claim:** YAP/TEAD-dependent enhancer regulation under ECM stiffness has been explored conceptually (though not fully mapped, as established by the literature gap identified in this session). MRTF/SRF-dependent transcription under stiffness is described (Connelly et al., Nat Mater 2010; MRTF nuclear localization on stiff ECM is established [GROUNDED]), but no paper has asked which specific ENHANCERS carry SRF/CArG motifs and gain H3K27ac under ECM stiffness, nor whether the MRTF/SRF enhancer program is distinct from, redundant with, or antagonistic to the YAP/TEAD enhancer program at the same stiffness range. The specific predictions are: (a) MRTF/SRF activates a non-overlapping set of enhancers from those activated by YAP/TEAD under identical stiffness conditions (because CArG elements and TEAD elements are distinct DNA sequences with different genomic distributions); (b) MRTF nuclear translocation precedes YAP nuclear translocation kinetically under acute stiffness shifts (because F-actin polymerization is faster than LATS1/2 inhibition), activating a "first-responder" enhancer wave; (c) the CArG-enhancer wave controls cytoskeletal gene expression (actin isoforms, myosin light chain, calponin) while the TEAD-enhancer wave controls growth factor and proliferative gene expression — meaning the two programs control orthogonal aspects of the stiffness phenotype.

**Mechanism:**

Step 1 — ECM stiffness (>5 kPa) increases cytoskeletal tension via integrin-RhoA-ROCK signaling, stimulating F-actin polymerization (nucleated by formins, mDia1/2) [GROUNDED: Wozniak and Chen, Nat Rev Mol Cell Biol 2009 — RhoA/ROCK/actin mechanotransduction]. Filamentous actin sequesters MRTF-A (MAL/MKL1) and MRTF-B (MKL2) in the cytoplasm via their RPEL domains, which bind G-actin (monomeric actin) preferentially [GROUNDED: Miralles et al., Cell 2003 — the RPEL domain of MRTF-A binds G-actin; when G:F-actin ratio decreases due to polymerization, MRTF is released]. On stiff ECM, the G:F-actin ratio decreases as actin polymerizes into stress fibers, releasing MRTF from G-actin sequestration and allowing nuclear translocation (timescale: 15-30 min for MRTF nuclear translocation on stiff ECM, slightly faster than YAP (15-60 min) because MRTF responds directly to G-actin concentration while YAP requires LATS1/2 phosphorylation cascade).

Step 2 — Nuclear MRTF/SRF complex binds CArG elements [CC(A/T)6GG consensus motif, approximately 1,200 high-confidence CArG sites genome-wide; GROUNDED: Esnault et al., Genes Dev 2014 identified CArG elements by SRF ChIP-seq]. SRF is constitutively nuclear; MRTF nuclear translocation is the regulated event that converts SRF from a low-activity to high-activity state [GROUNDED: canonical MRTF/SRF model]. At CArG-containing enhancers, the MRTF-SRF complex recruits co-activators: EP300 has been reported as an SRF co-activator (Bhatt et al., Mol Cell Biol 1999 [PARAMETRIC: citation from parametric knowledge; SRF-EP300 interaction reported but not confirmed by STRING in blind mode]) and p300 can acetylate H3K27 at CArG-bound SRF targets. Alternatively, the Mediator complex (specifically MED12) is a well-established SRF co-activator.

Step 3 — The CArG enhancer landscape under stiffness: SRF/MRTF targets include genes encoding cytoskeletal components (ACTA2/alpha-smooth muscle actin, VCL/vinculin, TAGLN/SM22-alpha, MYL9/MLCK), adhesion molecules, and ECM components. The enhancers controlling these genes are predicted to carry CArG elements and gain H3K27ac under stiff ECM conditions proportional to MRTF nuclear accumulation. This is a mechanistically distinct program from YAP/TEAD targets (which include CTGF, CYR61, ANKRD1, proliferative genes) — the MRTF program drives cytoskeletal remodeling while the YAP program drives cell growth.

Step 4 — The crossover insight from H4 (nuclear architecture): do CArG enhancers show differential LAD preference compared to TEAD enhancers? The hypothesis predicts that CArG enhancers (controlling cytoskeletal genes) are depleted from LADs, similar to TEAD enhancers, because cytoskeletal gene regulatory elements are constitutively accessible in mesenchymal cells. However, the MRTF/SRF program controls IMMEDIATE-EARLY stiffness responses (cytoskeletal remodeling, within 30-120 min) while the YAP/TEAD program controls SUSTAINED stiffness responses (growth factors, matrix remodeling, 2-24 hr). This temporal separation makes the MRTF program a "mechanical first-responder" and the YAP program a "sustained effector" — a distinction that has not been experimentally validated at the enhancer level.

Step 5 — Quantitative coupling between MRTF nuclear concentration and CArG enhancer H3K27ac: MRTF nuclear localization is graded with F-actin assembly, which scales with stiffness. The prediction is: H3K27ac gain at CArG enhancers is linearly proportional to MRTF nuclear intensity (measurable by MRTF-A immunofluorescence), while H3K27ac gain at TEAD enhancers is proportional to YAP nuclear intensity. The two enhancer programs can be decoupled pharmacologically: cytochalasin D (F-actin depolymerization, depletes nuclear MRTF without affecting YAP in some contexts) vs verteporfin (YAP/TEAD inhibitor, does not directly affect MRTF).

**Predicted observation:** MCF10A cells and/or primary human MSCs on PAA hydrogels at 1, 5, 10, 25 kPa (48 hr). Primary assay: H3K27ac CUT&Tag + MRTF-A immunofluorescence + YAP immunofluorescence at the same stiffness conditions. SRF CUT&RUN (anti-SRF, Santa Cruz sc-335) to define CArG-occupied sites genome-wide. MRTF-A CUT&RUN to define MRTF-dependent occupancy.

Primary predictions:
(a) SRF-occupied CArG elements genome-wide are partitioned into stiffness-responsive (gain H3K27ac on stiff vs soft ECM) and stiffness-insensitive subsets. The stiffness-responsive CArG enhancers are those with increased MRTF-A occupancy on stiff ECM.
(b) Stiffness-responsive CArG enhancers and stiffness-responsive TEAD enhancers show less than 20% overlap at any stiffness (non-redundant programs).
(c) MRTF-A nuclear translocation precedes YAP nuclear translocation by 10-20 min on acute stiffness shift (transfer from 1 kPa to 10 kPa hydrogels using a stiffness-switchable photoactivatable PAA system, or by transferring cells from fibronectin-coated coverslips to pre-equilibrated PAA gels).
(d) Cytochalasin D (1 uM, 30 min) on stiff ECM: reduces MRTF nuclear localization and reduces H3K27ac at CArG enhancers, without reducing YAP nuclear localization or H3K27ac at TEAD enhancers (demonstrating pathway independence).
(e) At MSCs on stiff ECM, the CArG enhancer program correlates with early cytoskeletal gene expression (ACTA2, VCL at 4-8 hr) while the TEAD enhancer program correlates with late growth/ECM gene expression (CTGF, CYR61 at 8-24 hr).

**Falsification:**

(1) If CArG enhancers and TEAD enhancers significantly overlap (>50% of stiffness-responsive CArG enhancers are also TEAD-occupied), the two programs are not orthogonal and MRTF and YAP co-regulate the same enhancers — the "two-program" model is wrong.

(2) If cytochalasin D reduces both MRTF nuclear localization AND YAP nuclear localization (both pathways require F-actin), the two programs cannot be pharmacologically decoupled and the experimental design is confounded. In this case, a more specific MRTF inhibitor (CCG-203971, a MRTF-SRF pathway inhibitor) would be needed.

(3) If MRTF nuclear translocation does NOT precede YAP translocation kinetically (both occur at 15-60 min), the "first-responder" temporal separation model is wrong.

(4) If there is no H3K27ac gain at CArG-containing enhancers under stiff ECM (only at CArG-containing promoters), SRF regulates cytoskeletal genes through promoter-proximal mechanisms and the enhancer program is absent.

**Test protocol:** MCF10A cells on PAA hydrogels (1, 5, 10, 25 kPa; n=3 biological replicates). 48 hr culture. SRF CUT&RUN (anti-SRF, Santa Cruz sc-335; 0.5 ug antibody per 500k cells) to identify CArG-occupied sites at each stiffness. MRTF-A CUT&RUN (anti-MRTF-A/MKL1, CST #14760) for occupancy. H3K27ac CUT&Tag for mark deposition. YAP immunofluorescence + MRTF-A immunofluorescence at 15, 30, 60, 120 min post-transfer to stiff ECM (acute timecourse to compare translocation kinetics). Pharmacological: cytochalasin D (1 uM, 30 min pre-treatment) vs verteporfin (1 uM, 1 hr, YAP inhibitor) to dissect the two pathways. Gene expression: RT-qPCR for MRTF targets (ACTA2, VCL, TAGLN) and YAP targets (CTGF, CYR61, ANKRD1) at 2, 4, 8, 24 hr post-stiffness shift. Motif analysis: HOMER/MEME for de novo motif discovery in stiffness-responsive CArG enhancers vs TEAD enhancers to confirm identity and non-overlap. LAD overlay (from lamin B1 CUT&RUN, as in H4-v2 protocol) to assess whether CArG enhancers show similar or different LAD distribution compared to TEAD enhancers.

**Confidence:** 0.50 — New for cycle 2 (replacing H5's 0.55 adjusted down by Critic). The MRTF/SRF mechanosensing pathway under stiffness is established. The gap in MRTF-dependent ENHANCER profiling (vs. promoter-focused studies) is real. The temporal first-responder prediction is quantitatively grounded (MRTF kinetics faster than YAP via G-actin release vs LATS phosphorylation cascade). Key uncertainty: whether SRF/MRTF actually recruits HAT activity (EP300 or alternative) to deposit H3K27ac at CArG elements under stiffness — this is the least grounded step.

**Groundedness:** 6 — MRTF/SRF mechanosensing pathway (Miralles 2003, Connelly 2010, Olson and Nordheim 2010) [GROUNDED]. G-actin-dependent MRTF sequestration [GROUNDED]. CArG elements and SRF targets genome-wide (Esnault 2014) [GROUNDED]. RhoA/ROCK/F-actin under ECM stiffness [GROUNDED]. The claim that H3K27ac is deposited at CArG enhancers under stiffness (as opposed to just CArG promoters) is PARAMETRIC. The SRF-EP300 interaction is PARAMETRIC (cited from parametric knowledge; not STRING-verified in this session). The temporal kinetics (MRTF faster than YAP) is a PARAMETRIC prediction from mechanism, not direct measurement.

**Key uncertainty:** Whether MRTF/SRF recruits HAT activity (EP300, CBP, or PCAF) to distal CArG elements or only to proximal promoter-bound SRF sites. Many CArG elements are at the +/-1-2 kb region relative to TSS rather than at distal enhancers (>10 kb from TSS). If MRTF primarily controls promoter-proximal H3K27ac rather than distal enhancer H3K27ac, this hypothesis is more about mechanosensitive promoter activation than enhancer regulation per se. The experimental design specifically isolates distal CArG elements (>2 kb from TSS) to address this.

**Counter-evidence:**

(1) Cytochalasin D and other F-actin depolymerizing agents also reduce YAP nuclear localization (because YAP nuclear retention requires actin-dependent nuclear pore dynamics and cytoskeletal tension that also depends on F-actin). Pharmacological decoupling of MRTF from YAP may be difficult with available tool compounds.

(2) MRTF/SRF primarily controls smooth muscle and myofibroblast gene programs, and MCF10A (mammary epithelial) cells may have low baseline SRF activity with few CArG-occupied enhancers. The more relevant cell type may be primary fibroblasts or MSCs, where the cytoskeletal/contractile gene program is more active.

(3) Connelly et al. 2010 (MRTF/SRF under stiffness) measured transcriptional outcomes, not chromatin states. It is possible that MRTF-dependent gene activation under stiffness occurs without H3K27ac gain at distal enhancers (via direct activation at promoters with no enhancer involvement), making this hypothesis an enhancer-centric reframing of a promoter-mediated process.

**Cross-domain creativity score:** 3 (mechanobiology + enhancer epigenomics + cytoskeletal biology / muscle differentiation)

---

# Evolution Quality Check

## 1. Diversity Check

| ID | Primary mechanosensor | Bridge mechanism (unique?) |
|----|----------------------|-----------------------------|
| H4-v2 | Lamin A/C stiffness-scaling → cLAD geometry | Nuclear architecture creates a spatial whitelist encoded in constitutive LAD boundaries |
| H2-v2 | KDM6B (stiffness-induced demethylase) as rate-limiting gate | Sequential enzymatic gating: demethylation unlocks acetylation; temporal lag is the key signature |
| H5-v2 | MRTF/SRF actin-dependent nuclear translocation (YAP-independent) | CArG enhancer first-responder wave orthogonal to TEAD enhancer sustained program |

No two hypotheses share a bridge mechanism. H4-v2 is about which enhancers CAN respond (spatial filter). H2-v2 is about HOW bivalent enhancers are temporally sequenced to become active. H5-v2 is about a PARALLEL mechanosensing pathway with a distinct TF and distinct enhancer set. Diversity constraint: SATISFIED.

## 2. Novelty Preservation

- H4-v2: Novel claim from parent (LAD enhancer stiffness resistance) is preserved and sharpened by the cLAD/fLAD stratification. The new element (LMNA-R386K perturbation, OR > 4 threshold, stiffness dose-dependence of the OR) adds testability without diluting the core claim.
- H2-v2: Novel claim from parent (stiffness coordinating two H3K27-modifying enzymes at the same residue) is preserved; the reframing from "simultaneous" to "sequential gate" makes the claim stronger, not weaker, because it adds a distinctive kinetic signature that is uniquely testable.
- H5-v2: The parent's novel claim (mechanical memory via EP300-BRD4 feedback) has been replaced by a different novel claim (MRTF/SRF as a YAP-parallel mechanosensitive enhancer program). This is a mutation, not preservation, but was necessary because the parent's quantitative basis was fatally flawed. The replacement claim is independently novel and directly addresses the Critic's systematic gap #1.

## 3. Critic Revision Compliance

| Mandatory revision | H4-v2 | H2-v2 | H5-v2 |
|---|---|---|---|
| H4: Null expectation for >90% prediction | DONE (OR > 4 vs random, powered calculation) | N/A | N/A |
| H4: siLMNA confound | DONE (replaced with LMNA-R386K point mutant) | N/A | N/A |
| H2: KDM6B vs UTX at enhancers | N/A | DONE (siKDM6B + siKDM6A separately) | N/A |
| H2: Temporal asynchrony | N/A | DONE (reframed as sequential gate; lag-phase prediction added) | N/A |
| H2: Yu 2025 thyroid cancer caveat | N/A | DONE (explicitly acknowledged) | N/A |
| H2: CBP compensation | N/A | DONE (A-485 + SGC-CBP30 combination) | N/A |
| H5: Lower memory half-life | N/A | N/A | Resolved by mutation (memory mechanism abandoned) |
| H5: Triptolide control | N/A | N/A | Resolved by mutation |
| Meta: MRTF/SRF gap | N/A | N/A | DONE (H5-v2 is entirely MRTF/SRF-based) |

All mandatory revisions incorporated.

## 4. Quantitative Plausibility

- **H4-v2 OR > 4 threshold**: LADs cover ~35-40% of the genome; ~65% of any random enhancer set is non-LAD. If stiffness-responsive enhancers were at OR = 1 (no enrichment), 65% would be non-LAD. If OR = 4 (the prediction): approximately 88% would be non-LAD (using the formula: OR = [p/(1-p)] / [0.65/0.35], solving for p gives ~0.88). This is slightly below the parent's original ">90%" claim but requires a detectable enrichment above baseline. With 100-200 stiffness-responsive enhancers in a typical CUT&Tag experiment, a 4x enrichment corresponds to ~30-50 expected cLAD enhancers in the responsive set if random, vs ~12-15 if the filter operates. This is detectable with a Fisher's exact test at n = 100-200 enhancers. The threshold is quantitatively appropriate.

- **H2-v2 lag phase 4-8 hr**: KDM6B is a transcriptional target requiring mRNA induction → translation → nuclear import → chromatin binding. Typical protein accumulation timescale after transcriptional induction: 2-6 hr for a nuclear protein in a dividing cell (mRNA half-life ~2-4 hr, translation ~30 min, nuclear import ~30 min). This gives a 4-8 hr lag before effective KDM6B activity at enhancers, which is consistent with H3K27me3 demethylation beginning at 4-8 hr and H3K27ac gain at 8-16 hr. The prediction is kinetically plausible. Counter-consideration: if KDM6B is regulated post-translationally (faster), the lag could be shorter. This is acknowledged in falsification criterion (3).

- **H5-v2 MRTF faster than YAP (10-20 min)**: MRTF nuclear translocation requires only F-actin polymerization → G-actin depletion → RPEL domain release → passive/active nuclear import. YAP nuclear translocation requires: LATS1/2 phosphorylation (requires RhoA → ROCK → PP2A activation, a multi-step cascade) → YAP dephosphorylation → XPO1-dependent nuclear retention. The MRTF pathway has fewer steps. Measured timescale: 15 min for MRTF nuclear accumulation after serum stimulation (Miralles 2003); 15-60 min for YAP in response to substrate stiffness changes (Dupont 2011). A 10-20 min head start for MRTF is plausible but the overlap range (15-30 min both) means the difference may be small. Quantitative plausibility: CONDITIONAL — the first-responder claim is plausible but the magnitude of the temporal separation may be within experimental error. This is noted as a key uncertainty.
